title: [Pharmacokinetic and clinical studies on flomoxef in the perinatal period in obstetrics and gynecology].
abstract: Pharmacokinetic and clinical studies on flomoxef (FMOX) in the perinatal period in obstetrics and gynecology were performed and the results obtained are summarized as follows: 1. Concentrations of FMOX in maternal serum, umbilical cord serum and amniotic fluid were determined after intravenous injection of 1 g. The maternal serum concentration was 41.9 micrograms/ml at 16 minutes after administration, and gradually decreased thereafter to 1.36 micrograms/ml at 5 hours 19 minutes. The concentration of FMOX in umbilical cord serum was 17.5 micrograms/ml at 16 minutes after administration, then gradually decreased thereafter, was slightly higher than that in maternal serum after approx. 3 hours and was 2.88 micrograms/ml at 5 hours 19 minutes. The amniotic fluid concentration was 0.31 micrograms/ml at 16 minutes after administration, increased to 7.85-15.8 micrograms/ml at approx. 3 hours, and gradually decreased while maintaining relatively high levels. 2. One or two grams of FMOX were given by intravenous drip infusion twice daily to 17 patients with perinatal infections for 5 to 7 days. Clinical efficacies were evaluated as excellent in 7 cases and good in 10, suggesting that FMOX was effective in all cases. No subjective side effects were observed in any of the 17 patients. As to abnormal laboratory findings, a minor degree of elevation of GPT was observed in 1 patient and that of GOT.GPT in 1. No other abnormal changes in laboratory examinations were observed. Considering the above results, we conclude that FMOX is a useful antibiotic in perinatal infections.
authors.affiliation: Department of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine.
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
authors.forename: J
authors.initials: J
authors.lastname: Yasuda
authors.forename: H
authors.initials: H
authors.lastname: Okada
authors.forename: K
authors.initials: K
authors.lastname: Iwasaku
mesh_terms: D000328:Adult; D000653:Amniotic Fluid / Q000378:metabolism; D002511:Cephalosporins / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004341:Drug Evaluation; D004716:Endometritis / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D005312:Fetal Blood / Q000378:metabolism; D006801:Humans; D007231:Infant, Newborn; D008413:Mastitis / Q000188:drug therapy* / Q000378:metabolism; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000378:metabolism; D011704:Pyelonephritis / Q000188:drug therapy / Q000378:metabolism
chemical_list: D002511:Cephalosporins; C045693:flomoxef